MOLOGEN FORSCHUNGS ENTWICKLUNG has a total of 22 patent applications. Its first patent ever was published in 1999. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are SAIBA GMBH, NEMOD IMMUNTHERAPIE AG and AGRICULTURAL TECH RES INST.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Australia | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Germany | 3 | |
#5 | China | 2 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Wittig Burghardt | 18 |
#2 | Schroff Matthias | 13 |
#3 | Junghans Claas | 8 |
#4 | Lutz Hans | 5 |
#5 | Leutenegger Christian | 5 |
#6 | Hoffmann Friedrich | 3 |
#7 | Pedersen Nils | 3 |
#8 | Fuertes Laura Lopez | 2 |
#9 | Dorbic Tomislav | 2 |
#10 | Jimenez Marcos Timon | 2 |
Publication | Filing date | Title |
---|---|---|
AU2002246012A1 | Beta-endorphin/crf gene therapy for locally combating pain | |
EP1355661A2 | Tumor vaccine | |
DE10156679A1 | Genetic vaccine against Leishmania major | |
AU6683500A | Feline interleukin-12 as an immune stimulant | |
AU6683400A | Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat | |
DE10025920A1 | Methods and agents for treating immune reactions in the eye | |
DE19935756A1 | Covalently closed nucleic acid molecule for immune stimulation | |
EP0967274A2 | Method for producing dumbbell- shaped DNA molecules as expression constructs |